Quoin Pharmaceuticals reported positive 6-month clinical data from an ongoing pediatric Netherton Syndrome study, showing significant skin improvements and reduced itch. The FDA cleared a second pivotal study of QRX003 for Netherton Syndrome. Initial positive data was announced from a Peeling Skin Syndrome pediatric study. QRX003 received Orphan Drug Designation in Europe and Rare Pediatric Disease Designation in the US. The NETHERTON NOW campaign expanded with new patient and expert video releases.

Quoin Pharmaceuticals highlighted the positive clinical data from their ongoing pediatric Netherton Syndrome study and the versatility of QRX003 for rare skin diseases. The Company received important regulatory designations in both Europe and the US. They plan to initiate additional studies and focus on delivering the first approved therapy for Netherton Syndrome. Financially, Quoin had $7.8 million in cash as of June 30, 2025, supporting operations into Q1 2026.

In the second quarter of 2025, Quoin Pharmaceuticals made significant progress in their clinical development for Netherton Syndrome and Peeling Skin Syndrome. The Company received key regulatory designations and expanded their NETHERTON NOW campaign, raising awareness for effective treatment options. Financially, Quoin reported a net loss of $3.7 million for the quarter, primarily due to increased research and development expenditure.

Read more at GlobeNewswire: Quoin Pharmaceuticals Announces Second Quarter 2025